FDA official says the approval is important because of the combination of the flu season and the COVID-19 pandemic.
FDA expanded the approved indication for baloxavir marboxil (Xofluza, Genentech) to include post-exposure prevention of influenza for patients 12 years of age and older after contact with an individual who has the flu.
In addition, the drug, previously available only in tablet form, is now available as granules for mixing in water, FDA said in a press release.
Related: Gottlieb optimistic about COVID-19 end after positive Moderna vaccine results
“This expanded indication for Xofluza will provide an important option to help prevent influenza just in time for a flu season that is anticipated to be unlike any other because it will coincide with the coronavirus pandemic,” said Debra Birnkrant, M.D., director of the Division of Antiviral Products in the FDA’s Center for Drug Evaluation and Research. “Americans will have to be more vigilant than ever as these viruses spread concurrently.”
Xofluza was originally approved in 2018 for treating uncomplicated flu in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
Related: Pfizer: COVID-19 vaccine likely ready late November
Xofluza’s safety and efficacy for post-flu exposure prevention is supported by one randomized, double-blind, controlled trial.
The trial included around 600 subjects who were exposed to a person with influenza in their household. The trial’s primary endpoint was the proportion of subjects who were infected with influenza virus and presented with fever and at least one respiratory symptom from day 1 to day 10. Of those who received Xofluza, 1% of subjects met these criteria compared with 13% of those in the placebo group.
Read more: FDA approves game-changing influenza drug
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More